Lonza Stock - Sunday background on the Swiss CDMO group
21.06.2026 - 07:27:07 | ad-hoc-news.de
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 07:26 CET. Details in the imprint.
Lonza (CH0013841017) is one of Switzerland's best-known life science suppliers and a key contract manufacturer for the biopharmaceutical industry. With no fresh market-moving news from major wires or its own investor relations page today, this Sunday piece focuses on background, positioning and context for the stock.
All news and key data on Lonza stock
On quieter trading days, background on Lonza helps frame the stock's role in global biopharma supply chains and on the Swiss market.
Background on Lonza's role
Lonza describes itself as a global development and manufacturing partner to the pharmaceutical, biotech and nutrition industries, with activities from early research support to commercial-scale production of active ingredients and finished products. Company overview The group is headquartered in Basel and listed on the SIX Swiss Exchange.
The company has evolved from its historical roots in fine chemicals into a focused contract development and manufacturing organization, often abbreviated as CDMO, serving large pharma groups as well as smaller biotech innovators.
Operational footprint and segments
Lonza's current structure highlights biologics manufacturing, cell and gene technologies, small molecules and capsules as its core platforms, reflecting demand for complex therapies and specialized dosage forms. Latest reports and presentations These activities span multiple sites in Europe, North America and Asia.
Biologics facilities produce monoclonal antibodies and other large-molecule drugs at different scales, while the cell and gene business supports emerging modalities such as viral vectors used in advanced therapies.
How the business makes money
As a CDMO, Lonza generates revenue primarily through multi-year manufacturing and service contracts with pharmaceutical and biotech customers. Projects typically start with development work and scale-up, followed by commercial manufacturing once client products receive regulatory approval.
This model can create a relatively visible order book when key customers progress successfully, but it also exposes the company to project delays, clinical setbacks or changing demand for specific therapies.
What the company sells
Beyond its development services, Lonza is known for products such as its hard gelatin and vegetarian capsule lines used by pharmaceutical and nutrition customers around the world. These capsules form an important standardized product offering alongside bespoke manufacturing contracts.
Where the stock trades today
The shares of Lonza (CH0013841017) trade on the SIX Swiss Exchange in Zurich; a current Swiss franc quote was not reliably verifiable at the time of this Sunday background review.
Key facts on Lonza stock
- Company: Lonza Group AG
- ISIN: CH0013841017
- Ticker: LONN
- Venue: SIX Swiss Exchange
- Sector / Industry: Health Care - Life Sciences Tools & Services / CDMO
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
